Blog
RSS FeedPosted by Michael Wonder on 31 Aug 2025
FDA approval of Leqembi subcutaneous formulation charts path to combination therapies for Alzheimer's disease
29 August 2025 - Subcutaneous delivery increases accessibility and introduces potential for at home administration, following model of diabetes and ...
Posted by Michael Wonder on 27 Jan 2022
The certainty of uncertainty in health technology assessment
26 January 2022 - History is replete with stories of poor decisions—catastrophes that leaders might have averted, and great opportunities that ...
Posted by Michael Wonder on 27 Jan 2022
Positive Early Access to Medicines Scheme (EAMS) scientific opinion awarded to GBT’s voxelotor for the treatment of haemolytic anaemia due to sickle cell disease
27 January 2022 - Global Blood Therapeutics today announced that the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has awarded ...
Posted by Michael Wonder on 27 Jan 2022
Shortage of prescription infant formula worries parents
28 January 2022 - A shortage of prescription infant formula has parents worried about how they will feed their babies. ...
Posted by Michael Wonder on 27 Jan 2022
FDA grants breakthrough therapy designation for Dizal Pharmaceutical's DZD9008 in patients with locally advanced or metastatic non-small cell lung cancer harbouring EGFR Exon 20 insertion
27 January 2022 - Breakthrough therapy designation further demonstrates excellent clinical profile of DZD9008 (sunvozertinib). ...
Posted by Michael Wonder on 27 Jan 2022
TGA approves Tepmetko for patients with non-small-cell lung cancer
27 January 2022 - Tepotinib (Tepmetko) has provisional approval in Australia for the treatment of adult patients with locally advanced or ...
Posted by Michael Wonder on 27 Jan 2022
The price of cystic fibrosis drugs is still too high
27 January 2022 - The Swedish Dental and Pharmaceutical Benefits Agency, TLV, has decided that Kaftrio and Kalydeco for cystic fibrosis ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19: EMA recommends conditional marketing authorisation for Paxlovid
27 January 2022 - The EMA’s CHMP has recommended granting a conditional marketing authorisation for the oral antiviral medicine Paxlovid ...
Posted by Michael Wonder on 27 Jan 2022
Lantern Pharma receives rare paediatric disease and orphan drug designations for LP-184 for the treatment of atypical teratoid rhabdoid tumour
24 January 2022 - Lantern Pharma today announced that the U.S. FDA has granted both rare paediatric disease designation and orphan ...
Posted by Michael Wonder on 27 Jan 2022
COVID-19 vaccine weekly safety report (27 January 2022)
27 January 2022 - To 23 January 2022, the TGA has received 431 reports which have been assessed as likely to ...
Posted by Michael Wonder on 27 Jan 2022
Do federal price transparency regulations neglect oncology patients?
24 January 2022 - The National Cancer Institute has identified measuring, understanding, and addressing cancer-related patient financial hardship as a top ...
Posted by Michael Wonder on 27 Jan 2022
2022 April price disclosure cycle – indicative prices
27 January 2022 - Indicative 1 April 2022 prices resulting from the 2022 April Cycle of Price Disclosure have now been ...
Posted by Michael Wonder on 26 Jan 2022
Pfizer pushes to intervene in lawsuit seeking COVID vaccine information from FDA
27 January 2022 - Pfizer wants to intervene in a Texas federal lawsuit seeking information from the U.S. FDA used ...
Posted by Michael Wonder on 26 Jan 2022
Immunocore announces FDA approval of Kimmtrak (tebentafusp-tebn) for the treatment of unresectable or metastatic uveal melanoma
26 January 2022 - Kimmtrak is the first T cell receptor therapeutic to receive regulatory approval. ...
Posted by Michael Wonder on 26 Jan 2022
Former bowel cancer patient calls for NZ to fund drug she says saved her life
26 January 2022 - A woman with bowel cancer who was told she may have two years to live says ...
Posted by Michael Wonder on 26 Jan 2022
PHARMAC confirms access criteria for COVID-19 treatments
26 January 2022 - PHARMAC has today confirmed the access criteria for two COVID-19 treatments – baricitinib and casirivimab with ...